Eminent Healthcare Leader Appointed as Independent Non-Executive Chairman for Emyria Ltd

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on developing innovative treatments for mental health and neurological conditions, is pleased to announce the appointment of Greg Hutchinson as Independent Non-Executive Chairman.

HIGHLIGHTS

Strategic Appointment: Emyria welcomes Mr. Greg Hutchinson as Independent Non-Executive Chairman to bolster the Company's innovative mental health research and development programs

Extensive Healthcare Leadership: Greg Hutchinson's tenure as CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services underscores significant expertise in scaling frontline health services and research programs

New frontier in Psychedelic-Assisted Therapy: Emyria poised to become a global leader in psychedelic-assisted therapy, following Australia's historic legalisation of MDMA and psilocybin for specified mental health conditions ¹

Mr. Hutchinson has held leadership roles in rapidly scaling clinical services delivery for over 30 years, spending the last 13 as the CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services, subsidiaries of Sonic Healthcare Limited (ASX: SHL) an S&P/ASX 100 company.

Under Mr. Hutchinson’s tenure, Sonic HealthPlus has become the largest provider of occupational and community medical services in Australia with a workforce of over 1,800 employees and contractors operating across more than 40 metropolitan, regional and remote locations in all States and Territories. At any one time, Sonic HealthPlus attends to some 7,000 active clients, ranging from small entities to some of the world’s foremost corporations across all industry sectors, as well as large government contracts with major Commonwealth and State agencies.

Mr. Hutchinson is also the deputy CEO and a Director of Sonic Healthcare’s clinical services division which encompasses approximately 5,000 employees and 2,500 doctors across some of Australia’s leading healthcare businesses.

Notably, Mr. Hutchinson's professional background also encompasses the founding and scaling of innovative clinical delivery care models and commercial activities.

Mr. Hutchinson co-founded 5D Clinics, a Perth-based radiation oncology business pioneering radiosurgery with CyberKnife technology. The clinic, renowned for its advanced treatment of malignant and benign tumours, has become a key referral centre for Australian and international patients and is expanding across Australia.

Previously, Mr. Hutchinson founded a successful chain of private physiotherapy clinics across Australia which were eventually acquired by Sonic HealthPlus.

Mr. Hutchinson has served as a Board Member of Tennis Australia since 2015.

Dr. Stewart Washer, who has made invaluable contributions to Emyria as Chairman, will be stepping down to an unpaid advisory role where he will continue to provide strategic support for Emyria.

Emyria CEO and MD, Dr. Michael Winlo, praised Dr. Washer's leadership: "Stewart has been instrumental in our journey so far, laying the foundations of a company committed to personalised therapy and data acquisition to guide the development of innovative treatments to address unmet clinical needs.

“We are excited to welcome Greg, whose exceptional track record in founding and scaling clinical operations and healthcare management will be pivotal in our next growth phase, particularly in expanding our MDMA-assisted therapy program."

This transition comes at a crucial time as Emyria embarks on expanding its mental health treatment portfolio and impact. Having already provided care to over 15,000 patients through its clinical services subsidiary, Emerald Clinics, Emyria's recent acquisition of the Pax Centre3, a leading psychological trauma treatment centre, further amplifies its capability for frontline service delivery and evidence-based research. The Company's active clinical trial in MDMA-assisted therapy and the recent arrival of patient-ready drug supply into Australia highlights its preparedness and commitment to developing this novel treatment with an initial focus on patients with Post-Traumatic Stress Disorder (‘PTSD’) - a condition affecting ~ 1,000,000 Australians.²

Click here for the full ASX Release

This article includes content from Emyria Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.